Does Rallies show Form 4 insider transactions for QNRX?

Yes. Rallies tracks QNRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is QNRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for QNRX. It does not provide personalized investment advice.

QNRX (Quoin Pharmaceuticals, Ltd. American Depositary Shares) Stock Analysis - Insider Trades

Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX) is a publicly traded Healthcare sector company. As of May 21, 2026, QNRX trades at $5.06 with a market cap of $11.11M and a P/E ratio of 0.00. QNRX moved +0.00% today. Year to date, QNRX is -64.84%; over the trailing twelve months it is -38.17%. Its 52-week range spans $4.80 to $54.95. Analyst consensus is strong buy with an average price target of $35.00. Rallies surfaces QNRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading QNRX stock inside the company?

Recent QNRX insider activity includes LANGER DENNIS bought 15.15K, Carter Denise P. bought 555.56K, Myers Michael bought 555.56K, Dunn Gordon bought 122.22K, and Culverwell Anthony James bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

QNRX Key Metrics

Key financial metrics for QNRX
Metric	Value
Price	$5.06
Market Cap	$11.11M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$54.95
52-Week Low	$4.80
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.80M
Gross Margin	0.00%

Recent QNRX Insider Trades

LANGER DENNIS bought 15.15K (~$128.64K) on Oct 14, 2025.
Carter Denise P. bought 555.56K (~$250.00K) on Dec 23, 2024.
Myers Michael bought 555.56K (~$250.00K) on Dec 23, 2024.
Dunn Gordon bought 122.22K (~$55.00K) on Dec 23, 2024.
Culverwell Anthony James bought 100.00K (~$45.00K) on Dec 23, 2024.

Latest QNRX News

Quoin Pharmaceuticals Earns FDA Fast Track, MHLW Orphan Designations, Targets 2027 NDA — May 7, 2026
Quoin Pharmaceuticals Plans Q3 2026 QRX009 Trials in Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex — Apr 28, 2026
Quoin Raises $104.5M, Gains Orphan and Fast Track Designations for QRX003 — Mar 26, 2026

QNRX Analyst Consensus

3 analysts cover QNRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.00.

Common questions about QNRX

Who is trading QNRX stock inside the company?: Recent QNRX insider activity includes LANGER DENNIS bought 15.15K, Carter Denise P. bought 555.56K, Myers Michael bought 555.56K, Dunn Gordon bought 122.22K, and Culverwell Anthony James bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for QNRX?: Yes. Rallies tracks QNRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is QNRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for QNRX. It does not provide personalized investment advice.